This is a randomized, double-blind, active-controlled, multi-center study to evaluate the efficacy of AXS-05, compared to bupropion, in preventing the relapse of depressive symptoms in subjects with major depressive disorder (MDD) who have responded to treatment with AXS-05.
Major Depressive Disorder
This is a randomized, double-blind, active-controlled, multi-center study to evaluate the efficacy of AXS-05, compared to bupropion, in preventing the relapse of depressive symptoms in subjects with major depressive disorder (MDD) who have responded to treatment with AXS-05.
A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms
-
Clinical Research Site, Bellflower, California, United States, 90706
Clinical Research Site, Lafayette, California, United States, 94549
Clinical Research Site, Oceanside, California, United States, 92056
Clinical Research Site, Redlands, California, United States, 92374
Clinical Research Site, Riverside, California, United States, 92506
Clinical Research Site, San Diego, California, United States, 92103
Clinical Research Site, Upland, California, United States, 91786
Clinical Research Site, Brandon, Florida, United States, 33511
Clinical Research Site, Doral, Florida, United States, 33122
Clinical Research Site, Hialeah, Florida, United States, 33012
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to 65 Years
ALL
No
Axsome Therapeutics, Inc.,
2026-03